Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-06-16
1995-10-24
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 530304, A61K 3828, C07K 1462
Patent
active
054610311
ABSTRACT:
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
REFERENCES:
patent: 2538018 (1951-01-01), Krayenbuhl et al.
patent: 2801953 (1957-08-01), Dorzbach et al.
patent: 2849370 (1958-08-01), Petersen et al.
patent: 3060093 (1962-10-01), Poulsen et al.
patent: 3868358 (1975-02-01), Jackson
patent: 5028587 (1991-07-01), Dorschug et al.
patent: 5149777 (1992-09-01), Hansen et al.
patent: 5164366 (1992-11-01), Balschmidt et al.
Howey, et al., Diabetes, 43, 396-402 (Mar. 1994).
Diabetes, 41, Suppl. 1, 192A (1992).
Brems, et al., Protein Engineering, 5:6, 519-525 (1992).
Heinemann, et al., Diabetologia, 33, 384-386 (1990).
Kirk-Othmer, Encyclopedia of Chemical Technology 13, 607-614 (1981).
Bruce H. Frank, Text and Slide copies of lecture given at the Conference on Insulin, Self Association and Conformational Studies on Human Proinsulin and Insulin Analogs, University of York, Aug. 29-Sep. 1, 1989.
Fullerton, et al., Biochim. Biophys. Acta, 214, 141-147 (1970).
Diabetologia, 30, 503A (1987).
Brange, et al., Nature, 333:16, 679-682 (Jun. 1988).
Brange, et al., Diabetes Care, 13:9, 923-954 (Sep. 1990).
Wollmer, et al., Phenol-Promoted Structural Transformation of Insulin in Solution, from the 2nd Assisi International Symposium on Advanced Models for the Therapy of Insulin-Dependent Diabetes, 903-911 (Apr. 1986).
Brange, Galenics of Insulin: The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations, Springer-Verlag Berlin Heidelberg, Germany (1987).
Simkin, et al., Biochimica Et Biophysica Acta, 200, 385-394 (1970).
Brems, et al., Protein Engineering, 5:6, 527-533 (1992).
Chen, et al., Proc. Natl. Sci. Counc, ROC(A), 6:3, 185-189 (1982).
Galloway, et al., Insulin Update, 111-119 (1982).
Balschmidt, et al., Acta Cryst, 975-986 (1991).
Krayenbul, et al., Crystalline Protamine Insulin (60-73).
Brange, et al., Structural Biology, 1, 934-940 (1991).
Chance, et al. Serial No. 08/057201, Filed May 5, 1993.
Boone David E.
Caltrider Steven P.
Dahling Gerald V.
Eli Lilly and Company
Prickril Benet
LandOfFree
Monomeric insulin analog formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monomeric insulin analog formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monomeric insulin analog formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1886646